Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Godaddy Inc (GDDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Godaddy Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Godaddy Inc trades at $91.57 (market cap $12.06B). The key difference: Godaddy Inc is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.
| BIO | GDDY | |
|---|---|---|
Market Cap | $8.04B | $12.06B |
Sector | Health | Technology |
52-Week High | $339.75 | $169.40 |
52-Week Low | $241.71 | $75.07 |
Enterprise Value | $7.85B | $14.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
GoDaddy (GDDY) trades at $90.86, up 2.18% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust fundamentals, including a 17.32% net income margin and a P/E of 14.4, while analyst consensus is a Buy with a $123 price target. However, recent news highlights a securities class action investigation, adding a layer of risk.
The outlook remains positive due to consistent earnings performance and solid cash flow, but investors should weigh the legal overhang and high debt levels against the stock's growth potential and attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
